6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease
6-K: Arexvy, Gsk's Respiratory Syncytial Virus Vaccine, Receives Positive European Medicines Agency Chmp Opinion for Adults Aged 50-59 at Increased Risk for Rsv Disease
葛蘭素史克公司的RSV疫苗Arexvy獲得歐洲藥品管理局CHMP的積極評價,適用於50-59歲患RSV疾病風險較高的成年人
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。